Public Employees Retirement System of Ohio Lowers Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Public Employees Retirement System of Ohio reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 0.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,095 shares of the company’s stock after selling 1,172 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Moderna were worth $9,630,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Intrinsic Value Partners LLC boosted its position in Moderna by 91.1% during the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after buying an additional 24,505 shares during the period. Banco Santander S.A. purchased a new stake in shares of Moderna during the third quarter worth about $3,550,000. John G Ullman & Associates Inc. boosted its holdings in shares of Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after purchasing an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MRNA shares. Sanford C. Bernstein began coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Leerink Partners dropped their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research report on Tuesday, September 17th. Barclays reduced their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Finally, HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $79.50.

Moderna Stock Down 0.1 %

Moderna stock opened at $42.82 on Friday. The business’s 50-day simple moving average is $48.62 and its two-hundred day simple moving average is $85.02. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a market cap of $16.48 billion, a PE ratio of -7.36 and a beta of 1.58. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.39) earnings per share. Equities analysts anticipate that Moderna, Inc. will post -9.32 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,379 shares of company stock valued at $158,195. Corporate insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.